The Apex Times
Above the Noise
Business Wire
BusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex TimesBusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex TimesBusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex TimesBusinessDisney’s ABC takes on the FCC in a First Amendment lawsuit, after a judge pressed it to slow downThe Apex TimesBusinessFDA approval expands Eli Lilly’s Mounjaro to help reduce heart attack and stroke risk in high-risk Type 2 diabetes patientsThe Apex TimesBusinessAmazon shares jump after Evercore flags “agentic” AI as a potential retail growth leverThe Apex TimesBusinessJim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worriesThe Apex TimesBusinessAmerican Airlines to expand seatback screens and raise premium seating share to compete more closely with DeltaThe Apex TimesBusinessNvidia’s stock moves are diverging from the chip index, with correlation near zero, Yahoo Finance reportsThe Apex TimesBusinessApple TV Plus price rises again to $14.99 a month, following industry-wide subscription pushThe Apex TimesBusinessDevon Energy trades at a discount versus ConocoPhillips, but both banks on shale cash flow and shareholder returnsThe Apex TimesBusinessBank of America to Pay $72.5 Million to Resolve Epstein-Related Claims, With a Compliance Warning AttachedThe Apex TimesBusinessNovo’s Wegovy pill draws China acceptance, but Lilly’s lead in the queue remains centralThe Apex TimesBusinessPfizer begins shipments of its updated COVID-19 vaccine aimed at older and high-risk patientsThe Apex TimesBusinessAmazon Keeps Its Pricing Software “For Now” as Antitrust Case Heads Toward TrialThe Apex Times
Back to front
RTX back in the spotlight after $22.9 billion Missile contract points to production ramp-up
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 28, 1:32 PM EDT

RTX back in the spotlight after $22.9 billion Missile contract points to production ramp-up

A seven-year U.S. contract for Tomahawk missile production, described as expanding output from 60 to 1,000 missiles per year, has renewed attention on RTX’s defense backlog and valuation, according to a report published Aug. 28.

3 min readEditor-approved Apex article

RTX is drawing fresh market attention after a report highlighted a sizable U.S. contract routed through the company’s Raytheon business unit to expand Tomahawk missile production. The agreement, described as valued at $22.9 billion over seven years, is framed as part of a broader effort by the U.S. military to accelerate inventory building for long-range strike capabilities.

In the account, the contract is expected to increase Tomahawk production from about 60 missiles per year to as many as 1,000 annually. That kind of step-change matters to defense contractors because missile programs often run for years and depend on long lead times for components, production lines, and government acceptance schedules.

The report also ties the potential production ramp to backlog and valuation concerns, arguing that RTX’s market price may not fully reflect the scale of the new work. It notes that RTX shares were trading around $212.08 at the time of publication on Aug. 28, presenting the contract as a catalyst that could alter investor expectations for future revenue and cash generation.

While the report’s framing centers on “undervaluation,” it does not, in the information provided here, lay out a detailed methodology such as discounted cash flow assumptions, backlog-to-revenue timing, or comparisons to peers’ defense backlog multiples. It also does not specify whether the $22.9 billion figure is the total contract value including all options, the portion already booked, or how much of the contract is expected to fall into which fiscal years.

RTX’s defense exposure is largely associated with long-running, high-dollar programs where governments place orders over multiple years and production must be scaled to meet both near-term readiness needs and longer-term sustainment. In that context, contract announcements tied to higher output rates can influence the outlook for backlog growth, utilization of manufacturing capacity, and the pace at which deliveries translate into recognized revenue.

For investors and analysts, the practical question is not only the topline size of the award but also how quickly the increased output rate can be achieved and maintained. Production ramps can be constrained by supply-chain availability, qualification and test timelines, and acceptance processes, any of which can affect when the higher volumes translate into earnings.

It remains unclear from the report details available here whether RTX disclosed additional conditions such as performance milestones, workforce or facility expansion requirements, specific procurement lots, or the share of work that flows through Raytheon versus other RTX operations. The company’s full contract terms, including delivery schedules and the portion already included in reported backlog at the time of publication, would be needed to assess how material the ramp is to near-term financial results.

Going forward, market watchers will likely focus on whether RTX and the U.S. government provide updates on production milestones, deliveries, and cost or schedule metrics tied to the Tomahawk ramp. Additional disclosures in investor materials, such as quarterly updates on defense backlog and program execution, may also clarify how management expects the award to flow through earnings over the seven-year period.

Why It Matters

  • If the production ramp is executed as described, it can meaningfully change the size and timing of RTX’s defense backlog and revenue recognition across multiple years.
  • Missile production scaling has operational implications, including supply-chain readiness and manufacturing capacity, which can affect execution risk and margins.
  • Large contract awards tied to output increases often become investor reference points for future procurement assumptions in defense programs.
  • The market reaction may depend on whether the higher-volume rate translates into deliveries and recognized revenue sooner than investors expect.

Sources

Key Facts

  • A report published Aug. 28 said RTX’s Raytheon business received a $22.9 billion, seven-year U.S. contract related to Tomahawk missile production.
  • The contract was described as enabling an increase in output from roughly 60 missiles per year to up to 1,000 missiles per year.
  • The report linked the contract to an expected backlog and valuation impact for RTX, framing the shares as potentially undervalued relative to the new work.
  • At the time of publication, the report stated RTX shares were trading around $212.08.
  • The information provided here does not include the full contract terms, delivery schedule, or how much of the award was already reflected in backlog figures when discussed.

Defense Related